MeSH term
Frequency | Condition_Probility | Adult | 6 | 0.0 |
Aged | 4 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Antigens, CD/*metabolism | 10 | 1.0 |
Antigens, Differentiation/*metabolism | 10 | 8.0 |
Cell Adhesion Molecules/metabolism | 2 | 0.0 |
Comparative Study | 4 | 0.0 |
Disease Progression | 2 | 0.0 |
Disease-Free Survival | 2 | 0.0 |
Female | 11 | 0.0 |
Humans | 66 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Male | 16 | 0.0 |
Middle Aged | 5 | 0.0 |
Prognosis | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 47 | 0.0 |
Antigens, CD/chemistry/metabolism | 2 | 20.0 |
Antigens, Differentiation/chemistry/metabolism | 2 | 40.0 |
Cells, Cultured | 7 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Alternative Splicing | 2 | 0.0 |
Amino Acid Substitution/genetics | 2 | 0.0 |
Animals | 34 | 0.0 |
*Antigens, Neoplasm | 2 | 1.0 |
Glycosylphosphatidylinositols/*metabolism | 2 | 3.0 |
Mice | 18 | 0.0 |
Mice, Inbred BALB C | 6 | 0.0 |
Rats | 8 | 0.0 |
Amino Acid Sequence | 14 | 0.0 |
Molecular Sequence Data | 17 | 0.0 |
Multigene Family | 3 | 0.0 |
Protein Binding/physiology | 2 | 0.0 |
Protein Structure, Tertiary | 11 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 20 | 0.0 |
Sequence Alignment | 6 | 0.0 |
Apoptosis | 2 | 0.0 |
Cadherins/metabolism | 2 | 1.0 |
Cell Division | 3 | 0.0 |
Down-Regulation | 3 | 0.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
Antigens, CD/metabolism | 2 | 0.0 |
Antigens, Differentiation/metabolism | 2 | 1.0 |
Cell Line | 10 | 0.0 |
Cell Line, Tumor | 11 | 0.0 |
Rats, Inbred F344 | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Sequence Homology, Amino Acid | 6 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Antigens, CD/analysis/*physiology | 2 | 7.0 |
Antigens, Differentiation/analysis/*physiology | 2 | 33.0 |
*Lymphocyte Activation | 3 | 0.0 |
Protein-Tyrosine-Phosphatase/physiology | 2 | 8.0 |
Cell Differentiation | 2 | 0.0 |
Base Sequence | 6 | 0.0 |
Binding Sites/genetics | 2 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Phylogeny | 4 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Ligands | 3 | 0.0 |
Protein-Tyrosine-Phosphatase/metabolism | 2 | 1.0 |
Time Factors | 6 | 0.0 |
Blotting, Western | 4 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Cell Separation | 3 | 0.0 |
Flow Cytometry | 3 | 0.0 |
Immunoblotting | 2 | 0.0 |
Microscopy, Confocal | 4 | 0.0 |
NF-kappa B/*metabolism | 2 | 0.0 |
Protein Binding | 8 | 0.0 |
Up-Regulation | 4 | 0.0 |
Glycosylphosphatidylinositols/metabolism | 2 | 3.0 |
Drug Resistance | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
Reference Values | 2 | 0.0 |
3T3 Cells | 2 | 0.0 |
Antigens, CD/genetics/*metabolism | 4 | 4.0 |
Antigens, Differentiation/genetics/*metabolism | 4 | 16.0 |
Cell Division/*physiology | 2 | 1.0 |
MAP Kinase Signaling System/physiology | 2 | 2.0 |
Phosphorylation | 5 | 0.0 |
Precipitin Tests | 4 | 0.0 |
Proteins/genetics/*metabolism | 2 | 0.0 |
Recombinant Fusion Proteins/metabolism | 3 | 0.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Hela Cells | 6 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Transfection | 10 | 0.0 |
Cell Adhesion Molecules/*metabolism | 3 | 1.0 |
Cell Adhesion | 7 | 0.0 |
Cytoplasm/metabolism | 4 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
Epithelial Cells/metabolism | 2 | 0.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
Kinetics | 4 | 0.0 |
Peptides/chemistry | 2 | 0.0 |
Protein Isoforms | 3 | 0.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Surface Plasmon Resonance | 2 | 1.0 |
Tumor Cells, Cultured | 6 | 0.0 |
Carcinoembryonic Antigen/*immunology | 2 | 11.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Binding Sites | 3 | 0.0 |
CHO Cells | 3 | 0.0 |
Cell Adhesion/*physiology | 2 | 1.0 |
Epitopes/immunology | 2 | 0.0 |
Hamsters | 4 | 0.0 |
Models, Molecular | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
Chickens | 2 | 0.0 |
Pregnancy | 4 | 0.0 |
Point Mutation | 2 | 0.0 |
Antigens, CD/*biosynthesis/genetics | 2 | 3.0 |
Antigens, Differentiation/*biosynthesis/genetics | 2 | 16.0 |
*Bacterial Adhesion | 2 | 4.0 |
Models, Biological | 4 | 0.0 |
Immunohistochemistry | 4 | 0.0 |
Antigens, CD/*genetics | 2 | 0.0 |
Antigens, Differentiation/*genetics | 2 | 1.0 |
Cell Adhesion Molecules/*genetics | 2 | 2.0 |
Mutagenesis | 2 | 0.0 |
COS Cells | 3 | 0.0 |
Carcinoembryonic Antigen/*genetics | 2 | 22.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
Endothelium, Vascular/cytology | 3 | 1.0 |
HT29 Cells | 3 | 1.0 |
Major Histocompatibility Complex | 2 | 0.0 |
Apoptosis/*physiology | 2 | 0.0 |
Drug Synergism | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Cell Division/genetics | 2 | 0.0 |
*Gene Expression Regulation, Neoplastic | 4 | 0.0 |
Hyperplasia | 2 | 0.0 |
Amino Acid Substitution | 2 | 0.0 |
Carcinoembryonic Antigen/genetics | 2 | 16.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Signal Transduction | 2 | 0.0 |
Antibodies, Monoclonal/chemistry | 2 | 2.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Carcinoembryonic Antigen/*metabolism | 3 | 33.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Antigens, CD/*physiology | 3 | 0.0 |
Antigens, Differentiation/*physiology | 3 | 3.0 |
Neoplasm Invasiveness | 2 | 0.0 |
DNA Primers | 2 | 0.0 |
Interferon Type II/*pharmacology | 2 | 0.0 |
Antigens, CD/genetics/*physiology | 2 | 5.0 |
Antigens, Differentiation/genetics/*physiology | 2 | 12.0 |
Mutation | 3 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Lung Neoplasms/immunology/*pathology | 2 | 28.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
